

16 March 2017

April 2017 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **April 2017** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Amiodarone hydrochloride (Lodi) inj 50 mg per ml, 3 ml ampoule– up to 6 inj available on a PSO (p'code 2496550)
- Aprepitant (Emend) cap 40 mg - Special Authority – Retail pharmacy (p'code 2520540)
- Leflunomide (Apo-Leflunomide) tab 10 mg (p'code 2511843) and 20 mg (p'code 2511851)
- Naproxen tab long-acting 750 mg (Naprosyn SR 750) (p'code 2518627) and tab long-acting 1 g (Naprosyn SR 1000) (p'code 2518619) – 28 tab pack size
- Pharmacy services (BSF Apo-Montelukast) brand switch fee – may only be claimed once per patient (p'code 2519593))
- Sumatriptan (Apo-Sumatriptan) tab 50 mg (p'code 100 tab pack 2519623, 102 tab pack 2519658) and 100 mg (p'code 100 tab pack 2519631, 102 tab pack 2519666)
- Venlafaxine (Enlifax XR) cap 37.5 mg (p'code 2509210), 75 mg (p'code 2509229) and 150 mg (p'code 2509237)

Changes to restrictions, chemical names and presentations

- Auranofin (Ridaura s29) tab 3 mg – addition of subsidy by endorsement
- Benzatropine mesylate tab 2 mg (Benztrop) and inj 1 mg per ml, 2 ml (Cogentin and Omega) – amended chemical name
- Clomifene citrate (Mylan Clomiphen and Serophen) tab 50 mg – amended chemical name
- Erlotinib (Tarceva) tab 100 mg and 150 mg – amended Special Authority criteria
- Influenza vaccine (Influvac) inj 45 mcg in 0.5 ml syringe – removal of Xpharm, addition of only on a prescription and no patient co-payment payable, and amended restriction
- Montelukast (Apo-Montelukast) tab 4 mg, 5 mg and 10 mg – addition of Brand Switch Fee payable
- Pirfenidone (Esbriet) cap 267 mg – removal of OP, addition of Wastage claimable

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Zinc and castor oil	Oint BP, 500 g	Multichem
Levonorgestrel	Tab 1.5 mg	Postinor-1

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Darunavir	Tab 400 mg and 600 mg	Prezista	
Paroxetine	Tab 20 mg	Apo-Paroxetine*	Loxamine
Terazosin	Tab 2 mg	Apo-Terazosin*	Arrow

* no subsidy changes for these brands for 1 April 2017.

Sumatriptan 50 mg and 100 mg tab

The Apo-Sumatriptan 50 mg and 100 mg tablets referred to above will be initially available as a 102 tablet pack size (17 blister strips of 6 tablets) from 1 April 2017. Once the initial stock is exhausted, (expected to be in 7-8 months), a 100 tablet pack size will be supplied for each strength. Both pack sizes will be listed from 1 April 2017.

Do you prefer email communications?

If you have not already contacted us and would like to receive future updates by email, please provide your email address to us at enquiry@pharmac.govt.nz. Please put "email or fax preference" in the subject line.

If email is not an option for you, and you would like to continue to receive faxed communications from us, please let us know that too.